LL-37(17-32)

Overview

LL-37 (17-32) is an ABCG2 inhibitor. LL-37 (17-32) binds to ABCG2, inhibits its transport activity in a non-competitive manner, and downregulates ABCG2 protein expression via lysosomal degradation. LL-37 (17-32) increases the accumulation of Mitoxantrone ( HY-13502 ) in cancer cells overexpressing ABCG2, thereby reversing mitoxantrone resistance. LL-37 (17-32) can be used in the research of multidrug-resistant cancers.

Application

Products | Products > Peptides | Products > Disease Areas > Cancer | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > BCRP

Product Information

• Catalog No.: HY-P5391
• CAS No.: 717919-61-4
• Molecular Formula: C95H161N29O21
• Molecular Weight: 2045.48
• Purity: 96.71%
• Storage: Sealed storage, away from moisture. Powder -80°C, 2 years , -20°C, 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
• Availability: In-stock

Source

Original product source